• Other

    Other
  • CN

    CN
  • EU

    EU
  • USA

    USA
    • My cart
    In the shopping cart is not goods, to choose and buy!
    • Product Name
    • Size
    • Quantity
    • Amount
      Selected items : 0 pieces Total : CHECK OUT()
      Ozanimod (RPC1063)
      Ozanimod (RPC1063)

      Price：
      Market Price：

      This product is for research use only, not for human use. We do not sell to patients.
      Number： - + Pieces（InventoryPieces）
      InvivoChem Cat #: V1507
      CAS #: 1306760-87-1Purity ≥98%

      Description: Ozanimod (formerly RPC-1063; trade name Zeposia) is a selective and orally bioavailable S1P Receptor 1 modulator that has been approved as an immunomodulatory medication for the treatment of relapsing multiple sclerosis and ulcerative colitis. Ozanimod acts as a sphingosine-1-phosphate receptor agonist with EC50 values of 160 ± 60 pM and 410 ± 160 pM for S1P1 receptors in the inhibition of cAMP generation and[35S]-GTPγS binding.  

      References: Br J Pharmacol. 2016 Jun;173(11):1778-92.

      Customer Validation
      Official Supplier of
      • VE
      • OF
      • YALE
      • hhmi
      • 香港大学
      Related Products
      Publications Citing InvivoChem Products
      • Physicochemical and Storage Information
      • Protocol
      • Quality Control Documentation
      • Related Biological Data
      • Customer Review
      Molecular Weight (MW)404.46
      FormulaC23H24N4O3
      CAS No.1306760-87-1
      Storage-20℃ for 3 years in powder form
      -80℃ for 2 years in solvent
      Solubility (In vitro)DMSO: 81 mg/mL (200.3 mM)
      Water: <1 mg/mL
      Ethanol: 10 mg/mL (24.7 mM)
      Other info

      Chemical Name: (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile

      InChi Key: XRVDGNKRPOAQTN-FQEVSTJZSA-N

      InChi Code: InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1

      SMILES Code: N#CC1=CC(C2=NC(C3=CC=CC4=C3CC[[email protected]@H]4NCCO)=NO2)=CC=C1OC(C)C           

      SynonymsRPC1063; RPC-1063; RPC 1063


      • Molarity Calculator
      • Dilution Calculator
      • The molarity calculator equation

        Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

        • Mass
        • Concentration
        • Volume
        • Molecular Weight *
        • =
        • ×
        • ×
      • The dilution calculator equation

        Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

        This equation is commonly abbreviated as: C1V1 = C2V2

        • Concentration (start)
        • ×
        • Volume (start)
        • =
        • Concentration (final)
        • ×
        • Volume (final)
        • ×
        • =
        • ×
        • C1
        •  
        • V1
        •  
        • C2
        •  
        • V2
      In Vitro

      In vitro activity: In S1P1R-HEK293T cells, Ozanimod induces sustained S1P1R internalization and degradation.

      Kinase Assay: Ozanimod is a potent and selective S1P1 and S1P5 receptor agonist with EC50s of 410±160 pM and 11±4.3 nM in [35S]-GTPγS binding, respectively. 

      Cell Assay: Ozanimod(RPC1063) was a specific agonist for S1P1 and S1P5 receptors. The EC50values were 160 ± 60 pM and 410 ± 160 pM for S1P1 receptors in the inhibition of cAMP generation and[35S]-GTPγS binding. The 83% Emax value of ozanimod against S1P5 receptor was 11 ± 4.3 nM. RPC1063 dose-dependently decreased S1P1 receptor re-expression on the cell surface and resulted in near complete and sustained loss of cell surface receptor expression at concentrations above 10 nM in S1P1 receptor-HEK293T cells after 1 h incubation.

      In VivoIn vivo, Ozanimod shows high oral bioavailability and volume of distribution. In a MOG-induced EAE mouse model, Ozanimod (3 mg/kg, p.o.) suppresses clinical symptoms. In a rat TNBS model of inflammatory bowel disease, Ozanimod (1.2 mg/kg, p.o.) inhibits clinical and histological disease scores. In a Naïve CD4+CD45Rbhi T cell adoptive transfer model, Ozanimod (1.2 mg/kg, p.o.) also significantly reduced disease severity as assessed by measuring the degree of inflammation, gland loss, hyperplasia, neutrophil infiltrate and mucosal thickness.
      Animal modelMOG-induced EAE model in C57Bl6 mice, TNBS model of inflammatory bowel disease in male Sprague Dawley rats, and Naive CD4+CD45Rbhi T cell adoptive transfer model in SCID mice
      Formulation & DosageDissolved in 5% DMSO, 5% Tween-20, 90% 0.1N HCl; 0.1-3 mg/kg; oral givage 
      References

      Br J Pharmacol. 2016 Jun;173(11):1778-92

      These protocols are for reference only. InvivoChem does not independently validate these methods.

      评论

        Home Prev Next Last page / pices

        发评论

        ×
        Your information is safe with us. * Required Fields.
        Products are for research use only;  We do not sell to patients
        Contact Us
        Contact Us
        Tel: 1-708-310-1919
        Fax: 1-708-557-7486
        Email: [email protected]
        Frequently Asked Questions
        Subscribe to our E-newsletter
        • Name*
        • *
        • E-mail*
        • *
        • instructions：
        • *
        Copyright 2020 InvivoChem LLC | All Rights Reserved
          Site map
        prompt
        Do you confirm the receipt?